Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.

Authors

Sam E. Mansour, George Washington University
Daniel F Kiernan
Daniel B Roth
David Eichenbaum
Nancy M Holekamp
Samer Kaba
Erica Werts

Document Type

Journal Article

Publication Date

3-1-2021

Journal

The British Journal of Ophthalmology

Volume

105

Issue

3

Inclusive Pages

414-419

DOI

10.1136/bjophthalmol-2020-315984

Comments

Epub 2020 May 27

APA Citation

Mansour, S. E., Kiernan, D., Roth, D., Eichenbaum, D., Holekamp, N., Kaba, S., & Werts, E. (2021). Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.. The British Journal of Ophthalmology, 105 (3). http://dx.doi.org/10.1136/bjophthalmol-2020-315984

Peer Reviewed

1